Navigation Links
Octapharma Launches Clinical Trial to Evaluate Efficacy & Safety of wilate® In Preventing Surgical Bleeding in Type 3 von Willebrand Disease Patients
Date:9/26/2011

s wilate® received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com or www.wilateusa.com.

Forward-looking statements

This news release contains forward-looking statements, which include known and unknown risks, uncertainties and other factors not under the company's control. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. These factors include results of current or pending research and development activities and actions by the FDA or other regulatory authorities.


'/>"/>
SOURCE Octapharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Octapharma USA Sponsors International Advisory Board for Evaluating Treatment of Patients with von Willebrand Disease
2. Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
3. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
4. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
5. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
6. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
7. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
9. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
10. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
11. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014  Medical Science Liaisons play a ... link between the medical device industry and key stakeholders, ... the coming years as the device industry relies on ... to research by benchmarking firm, Best Practices, LLC, one ... important edge is by harnessing new technology to enable ...
(Date:12/22/2014)... , Dec. 22, 2014 NxStage ... manufacturer of innovative dialysis products, announced today that ... cleared its System One™ to perform hemodialysis overnight ... as home nocturnal hemodialysis. NxStage,s® System One is ... the FDA for this indication. ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
(Date:12/25/2014)... ” was featured on NewsWatch as part of its monthly ... the iOS, Android, and Windows markets. Andrew Tropeano, a mobile ... and shared with viewers how this is an application for ... “A picture says a thousand words.” It’s true. There are ... because each picture holds a unique and special meaning. Photos ...
(Date:12/25/2014)... December 25, 2014 Residents at ... Community, recently showed their generous spirit by providing ... Catawba County Parenting Network- Grandparents Raising Grandchildren program. ... gathered around the largest Christmas tree on the ... purchased by residents of the Abernethy Village Association ...
(Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Retirement Community Residents Make Impact During Holiday Season 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3
... only cervical cancer vaccine, Gardasil, which has proved effective ... go on sale within weeks, the company //marketing it ... Merck & Co. Inc. has proved 100 percent effective ... Virus (HPV) which trigger most cervical cancers, reported the ...
... of H5N1 strain in Laos led to the mass culling ... in an egg-producing village in northeastern Thailand.// , ... Thailand through contaminated eggs trays. But they also said that ... disease effectively. Livestock Development chief Yukol Limlaemthong said that 78 ...
... Centre for Foreign Animal Disease (NCFAD) in Winnipeg, Manitoba, ... world organization //for animal health for bovine spongiform encephalopathy ... ,The Winnipeg lab can now provide scientific and technical ... techniques for diagnosis and perform checks for both the ...
... risk of several underlying medical complications, including heart disease and ... New England Research Institute in Massachusetts charted the health of ... looked at markers for metabolic syndrome, a sign of heart ... ,These markers include raised cholesterol, high blood sugar, ...
... According to recent research, MicroRNAs are fine targets for ... of Veterinary //Medicine have demonstrated how microRNA molecules are ... human colon cancer model. This process, known as angiogenesis, ... blood vessels to gorge on a steady ...
... in children affected by acute lymphoblastic leukemia and can ... other cardiovascular diseases//. ,It is the result ... of Genetic and Environmental Epidemiology and the Onco-Haematology Unit ... Division of the University of L'Aquila. ,Thrombosis ...
Cached Medicine News:Health News:Role Of MicroRNAs In Angiogenesis Researched 2Health News:Role Of MicroRNAs In Angiogenesis Researched 3Health News:Thrombosis, a Serious Risk in Children with Leukemia 2
Double-ended. Blades set at 45 and 90 degrees. Hexagonal handle....
5 mm curved blade. Round handle....
2 mm x 3 mm tapered blade. Referred to as "Number Two Knife". Angled 45 degrees. Round handle....
7 mm strong curved blade. Round handle....
Medicine Products: